Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BPH
MCID: PRS129
MIFTS: 51

Prostatic Hyperplasia, Benign (BPH)

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Prostatic Hyperplasia, Benign

About this section

MalaCards integrated aliases for Prostatic Hyperplasia, Benign:

Name: Prostatic Hyperplasia, Benign 57
Benign Prostatic Hyperplasia 55 73
Prostatic Hyperplasia 73
Bph 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
prostatic hyperplasia, benign:
Onset and clinical course infantile onset
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 600082
MedGen 42 C1704272
SNOMED-CT via HPO 69 263681008 266569009
Sources

Summaries for Prostatic Hyperplasia, Benign

About this section
OMIM : 57 Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth of the prostate gland, and is histologically defined as hyperplasia of the prostate gland. BPH is an age-related phenomenon in men beginning at about age 40 years. BPH may result in prostatic enlargement and clinical symptoms most commonly affecting the lower urinary tract. These symptoms may be obstructive, including hesitancy, weak flow, and urinary retention, or irritative, including increased frequency and urgency. However, not all men with histologic BPH will develop prostatic enlargement or urinary symptoms (review by Roehrborn, 2005). (600082)

MalaCards based summary : Prostatic Hyperplasia, Benign, also known as benign prostatic hyperplasia, is related to prostatic hypertrophy and prostate disease, and has symptoms including prostatism An important gene associated with Prostatic Hyperplasia, Benign is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Metabolism of steroid hormones. The drugs Saw palmetto and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and endothelial, and related phenotype is benign prostatic hyperplasia.

Wikipedia : 76 Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size... more...

Sources

Related Diseases for Prostatic Hyperplasia, Benign

About this section

Diseases related to Prostatic Hyperplasia, Benign via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 32.0 ADRA1A AR KLK3
2 prostate disease 31.2 AR CDKN2B-AS1 CYP17A1 FOLH1 KLK3 SERPINA3
3 prostatic adenoma 30.8 KLK3 SRD5A1
4 androgenic alopecia 30.5 AR KLK3 SHBG
5 sexual disorder 30.4 KLK3 PDE5A SHBG
6 suppression of tumorigenicity 12 30.3 AR FOLH1 KLK3
7 prostatitis 30.2 ADRA1A KLK3
8 alopecia, androgenetic, 1 30.2 AR SHBG SRD5A1 SRD5A2
9 gynecomastia 29.9 AR KLK3 SHBG
10 impotence 29.7 KLK3 PDE5A SHBG SRD5A1
11 prostate cancer 28.2 AR CDKN2B-AS1 CYP17A1 ESR2 FOLH1 KLK3
12 adenocarcinoma 10.5
13 aging 10.4
14 alopecia 10.3
15 insulin-like growth factor i 10.3
16 vaginitis 10.2 AR ESR2
17 47, xxy 10.2 AR SHBG
18 bladder cancer 10.2
19 body mass index quantitative trait locus 1 10.2
20 liver disease 10.2
21 urethral stricture 10.2
22 fatty liver disease 10.2
23 depression 10.2
24 gender identity disorder 10.1 AR ESR2
25 5-alpha reductase deficiency 10.1 SRD5A1 SRD5A2
26 sebaceous gland disease 10.1 AR SHBG
27 estrogen excess 10.1 ESR2 SHBG
28 testicular germ cell cancer 10.1 AR ESR2
29 psychosexual disorder 10.1 PDE5A SHBG
30 hermaphroditism 10.1 AR SRD5A2
31 cystitis 10.1
32 complete androgen insensitivity syndrome 10.1 AR SHBG
33 androgen insensitivity, partial 10.1 AR SHBG SRD5A1
34 withdrawal disorder 10.1 AR KLK3
35 pemphigus foliaceus 10.1
36 hermansky-pudlak syndrome 10.1
37 sex differentiation disease 10.0 AR CYP17A1 SHBG
38 postmenopausal atrophic vaginitis 10.0 AR ESR2 SHBG
39 breast cyst 10.0 KLK3 SERPINA3
40 transsexualism 10.0 AR CYP17A1 ESR2
41 cystitis cystica 10.0 AR KLK3
42 hypertension, essential 10.0
43 vesicoureteral reflux 1 10.0
44 mitochondrial import-stimulating factor 10.0
45 pulmonary disease, chronic obstructive 10.0
46 chronic kidney failure 10.0
47 diabetes mellitus 10.0
48 leukemia 10.0
49 lymphoma 10.0
50 neurogenic bladder 10.0

Graphical network of the top 20 diseases related to Prostatic Hyperplasia, Benign:



Diseases related to Prostatic Hyperplasia, Benign
Sources

Symptoms & Phenotypes for Prostatic Hyperplasia, Benign

About this section

Symptoms via clinical synopsis from OMIM:

57
Misc:
early age of onset

G U:
benign prostatic hyperplasia


Clinical features from OMIM:

600082

Human phenotypes related to Prostatic Hyperplasia, Benign:

32
# Description HPO Frequency HPO Source Accession
1 benign prostatic hyperplasia 32 HP:0008711

UMLS symptoms related to Prostatic Hyperplasia, Benign:


prostatism
Sources

Drugs & Therapeutics for Prostatic Hyperplasia, Benign

About this section

Drugs for Prostatic Hyperplasia, Benign (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Saw palmetto Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
2
Ethanol Approved Phase 4,Phase 1,Phase 2,Not Applicable 64-17-5 702
3
Finasteride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98319-26-7 57363
4
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 164656-23-9 6918296 152945
5
Doxazosin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 74191-85-8 3157
6
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106133-20-4 129211
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
8
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
9
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 81403-80-7 2092
10
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 171596-29-5 110635
11
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
12
Terazosin Approved Phase 4,Phase 2,Not Applicable 63590-64-7 5401
13 Mirabegron Approved Phase 4,Phase 2,Not Applicable 223673-61-8
14
Testosterone Approved, Investigational Phase 4,Phase 2 58-22-0 6013
15
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
16
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
17
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
18
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
19
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
20
Dihydrotachysterol Approved Phase 4,Phase 1,Phase 2 67-96-9 5281010 5311071
21
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
22
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
23
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
24
Tranexamic Acid Approved Phase 4 1197-18-8 5526
25
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
26
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
27
Prazosin Approved Phase 4,Phase 2,Not Applicable 19216-56-9 4893
28
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 77-92-9 311
30 Naftopidil Investigational Phase 4,Phase 3 57149-07-2
31
Dihydrotestosterone Illicit, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 521-18-6 10635
32
Fibrinolysin Investigational Phase 4 9004-09-5
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Saw palmetto extract Phase 4,Phase 3,Phase 2,Not Applicable
43 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Tolterodine tartrate Phase 4 124937-52-6
45 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
46 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
49 Platelet Aggregation Inhibitors Phase 4,Phase 3
50 calcium channel blockers Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 502)
# Name Status NCT ID Phase Drugs
1 A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPSâ„¢ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia Unknown status NCT01218672 Phase 4
2 Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
3 Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
4 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
5 Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients Unknown status NCT02006303 Phase 4
6 A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart Unknown status NCT00690950 Phase 4 Dutasteride
7 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
8 Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
9 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
10 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
11 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
12 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate Unknown status NCT02749604 Phase 4
13 Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
14 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
15 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP) Unknown status NCT00826527 Phase 4 Solifenacin PO
16 Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Completed NCT01259531 Phase 4 Silodosin
17 FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
18 Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
19 A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization Completed NCT00465101 Phase 4
20 Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
21 Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Completed NCT01757769 Phase 4 Silodosin
22 Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
23 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00401661 Phase 4 Alfuzosin
24 A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Completed NCT02757768 Phase 4 Mirabegron;Placebo;Tamsulosin Hydrochloride
25 Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Completed NCT00701779 Phase 4 Tamsulosin
26 Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
27 Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
28 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
29 Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
30 SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00486785 Phase 4 Alfuzosin
31 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
32 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
33 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
34 A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS). Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
35 Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement Completed NCT01294592 Phase 4 Dutasteride plus tamsulosin;tamsulosin
36 ALF-ONE : ALFuzosin ONcE Daily Completed NCT00280605 Phase 4 Alfuzosin
37 KTP Green Light Prostatectomy Compared With Open Prostatectomy Completed NCT02072499 Phase 4
38 PERmixon® in LUTS Evaluation Study (PERLES) Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
39 Once Daily Given Alfuzosin in the Treatment of BPH Completed NCT00637715 Phase 4 Alfuzosin
40 Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
41 A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding. Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
42 The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
43 Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study Completed NCT00427882 Phase 4 ALFUZOSIN
44 A Prospective Evaluation of the GreenLight Model 120 Laser Completed NCT00364585 Phase 4
45 A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation Completed NCT02180789 Phase 4 Tamsulosin OCAS
46 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4 Doxazosin mysylate GITS
47 Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH) Completed NCT00143221 Phase 4 Viagra;Placebo
48 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
49 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
50 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Completed NCT00827814 Phase 4 Dutasteride

Search NIH Clinical Center for Prostatic Hyperplasia, Benign

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Prostatic Hyperplasia, Benign

About this section
Sources

Anatomical Context for Prostatic Hyperplasia, Benign

About this section

MalaCards organs/tissues related to Prostatic Hyperplasia, Benign:

41
Prostate, Kidney, Endothelial, Testes, Spinal Cord, Liver, B Cells
Sources

Publications for Prostatic Hyperplasia, Benign

About this section

Articles related to Prostatic Hyperplasia, Benign:

(show top 50) (show all 1934)
# Title Authors Year
1
Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. ( 28624553 )
2018
2
Effects of<i>Panax ginseng</i>on the nerve growth factor expression in testosterone induced benign prostatic hyperplasia. ( 29379359 )
2018
3
Three-Year Outcomes of the Prospective, Randomized Controlled RezA<m System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. ( 29122620 )
2018
4
WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. ( 29360529 )
2018
5
Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. ( 30209896 )
2018
6
Increased risk of atrial fibrillation in patients with benign prostatic hyperplasia: A population-based cohort study. ( 30144121 )
2018
7
Acute urinary retention due to benign prostatic hyperplasia associated with cystitis glandularis in a 22-year-old patient. ( 30167057 )
2018
8
Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study. ( 29858589 )
2018
9
Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study. ( 30278528 )
2018
10
Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. ( 28414251 )
2018
11
Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia. ( 30355359 )
2018
12
Risk factors for urethral stricture and/or bladder neck contracture after monopolar transurethral resection of the prostate for benign prostatic hyperplasia. ( 30426880 )
2018
13
Two unusual reports of urogenital tuberculosis: One 'putty' kidney and another in association with benign prostatic hyperplasia. ( 30522625 )
2018
14
Diet-Induced Hyperinsulinemia as a Key Factor in the Etiology of Both Benign Prostatic Hyperplasia and Essential Hypertension? ( 30455570 )
2018
15
Anti-Proliferative Effects of HBX-5 on Progression of Benign Prostatic Hyperplasia. ( 30322186 )
2018
16
Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats. ( 30323905 )
2018
17
Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. ( 30332601 )
2018
18
Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. ( 30344644 )
2018
19
Patient-reported Goal Achievement after Treating Male Benign Prostatic Hyperplasia with Alpha-adrenergic Antagonist: A 12-week Prospective Multicenter Study. ( 30345500 )
2018
20
Banana Flower Extract Suppresses Benign Prostatic Hyperplasia by Regulating the Inflammatory Response and Inducing G1 Cell-cycle Arrest. ( 30348691 )
2018
21
Seminal vesicle abnormalities following prostatic artery embolization for the treatment of benign prostatic hyperplasia. ( 30355294 )
2018
22
A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study). ( 30358116 )
2018
23
Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications. ( 30359708 )
2018
24
Re: Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia. ( 30360296 )
2018
25
Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study. ( 30361957 )
2018
26
Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study. ( 30362173 )
2018
27
Editorial Comment to Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study. ( 30362175 )
2018
28
Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia. ( 30362688 )
2018
29
The Effect of Xialiqi Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats. ( 30364022 )
2018
30
Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride. ( 30367429 )
2018
31
Comparison of < 100 cc prostates and > 100 cc prostates undergoing aquablation for benign prostatic hyperplasia. ( 30370457 )
2018
32
Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. ( 30374274 )
2018
33
Effect of Veratrum maackii on testosterone propionate-induced benign prostatic hyperplasia in rats. ( 30381617 )
2018
34
Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. ( 30382600 )
2018
35
Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong. ( 30386234 )
2018
36
Re: A Prospective Randomised Placebo-controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). ( 30391083 )
2018
37
Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: A prospective study. ( 30402572 )
2018
38
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. ( 30410027 )
2018
39
Re: Is Early Benign Prostatic Hyperplasia (BPH) Treatment Worthwhile? ( 30412933 )
2018
40
Re: Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. ( 30412935 )
2018
41
Cost Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience. ( 30415110 )
2018
42
The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin. ( 30415813 )
2018
43
Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia? ( 30446471 )
2018
44
Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas. ( 30450670 )
2018
45
Outcome after prostatic artery embolization in patients with symptomatic benign prostatic hyperplasia. ( 30450921 )
2018
46
Prostatic Artery Embolization as a New Option in the Treatment of Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia - Current Evidence. ( 30457251 )
2018
47
Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α1 blocker and dutasteride to combination therapy with tadalafil and dutasteride. ( 30457437 )
2018
48
Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern. ( 30458721 )
2018
49
Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome. ( 30463466 )
2018
50
Metabolic syndrome is associated worsened erectile function in patients undergoing TURP due to benign prostatic hyperplasia. ( 30468407 )
2018
Sources

Variations for Prostatic Hyperplasia, Benign

About this section
Sources

Expression for Prostatic Hyperplasia, Benign

About this section
Search GEO for disease gene expression data for Prostatic Hyperplasia, Benign.
Sources

Pathways for Prostatic Hyperplasia, Benign

About this section

Pathways related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.42 AR KLK3 SRD5A1 SRD5A2
2
Metabolism of steroid hormones 66
Show member pathways
 11.38 CYP17A1 SRD5A1 SRD5A2
3
Steroid hormone biosynthesis 37
Show member pathways
 11.15 CYP17A1 SRD5A1 SRD5A2
4
Nongenotropic Androgen signaling 1
10.58 AR SHBG
5
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.12 CYP17A1 SRD5A1 SRD5A2
Sources

GO Terms for Prostatic Hyperplasia, Benign

About this section

Cellular components related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body fiber GO:0070852 8.62 SRD5A1 SRD5A2

Biological processes related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.69 CYP17A1 SRD5A1 SRD5A2
2 cell-cell signaling GO:0007267 9.67 ADRA1A AR ESR2 SRD5A2
3 male gonad development GO:0008584 9.63 AR SRD5A1 SRD5A2
4 response to testosterone GO:0033574 9.56 SRD5A1 SRD5A2
5 positive regulation of cardiac muscle hypertrophy GO:0010613 9.55 ADRA1A PDE5A
6 male genitalia development GO:0030539 9.54 SRD5A1 SRD5A2
7 androgen metabolic process GO:0008209 9.52 SRD5A1 SRD5A2
8 regulation of systemic arterial blood pressure GO:0003073 9.49 AR KLK3
9 hypothalamus development GO:0021854 9.48 SRD5A1 SRD5A2
10 cellular response to testosterone stimulus GO:0071394 9.43 AR SRD5A1
11 progesterone metabolic process GO:0042448 9.4 CYP17A1 SRD5A1
12 steroid biosynthetic process GO:0006694 9.33 CYP17A1 SRD5A1 SRD5A2
13 female genitalia development GO:0030540 9.32 SRD5A1 SRD5A2
14 response to follicle-stimulating hormone GO:0032354 9.26 SRD5A1 SRD5A2
15 androgen biosynthetic process GO:0006702 9.13 CYP17A1 SRD5A1 SRD5A2
16 sex differentiation GO:0007548 8.92 AR CYP17A1 SRD5A1 SRD5A2

Molecular functions related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.37 SRD5A1 SRD5A2
2 androgen binding GO:0005497 9.32 AR SHBG
3 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.26 SRD5A1 SRD5A2
4 amide binding GO:0033218 9.16 SRD5A1 SRD5A2
5 cholestenone 5-alpha-reductase activity GO:0047751 8.96 SRD5A1 SRD5A2
6 steroid binding GO:0005496 8.8 AR ESR2 SHBG
Sources

Sources for Prostatic Hyperplasia, Benign

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....